Research programme: bispecific monoclonal antibodies - Innovent Biologics/Eli Lilly

Drug Profile

Research programme: bispecific monoclonal antibodies - Innovent Biologics/Eli Lilly

Alternative Names: IBI 318; IBI 319

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Jul 2018 Preclinical trials in Cancer in China (unspecified route) (Innovent Biologics pipeline, July 2018)
  • 11 Oct 2015 Eli Lilly and Innovent Biologics expand research collaboration to develop and commercialise up to three anti-PD-1 based bispecific antibodies for Cancer
  • 20 Mar 2015 Eli Lilly and Innovent agree to co-develop a preclinical bi-specific monoclonal antibody in China for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top